Cargando…

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity

SIMPLE SUMMARY: The growing interest in BCL2 inhibitors for the treatment of multiple myeloma (MM) has led to the need for biomarkers that are able to predict patient’s sensitivity to the drug. The presence of the chromosomal translocation t(11;14) in MM is mainly associated with sensitivity to vene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todoerti, Katia, Taiana, Elisa, Puccio, Noemi, Favasuli, Vanessa, Lionetti, Marta, Silvestris, Ilaria, Gentile, Massimo, Musto, Pellegrino, Morabito, Fortunato, Gianelli, Umberto, Bolli, Niccolò, Baldini, Luca, Neri, Antonino, Ronchetti, Domenica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508148/ https://www.ncbi.nlm.nih.gov/pubmed/34638381 http://dx.doi.org/10.3390/cancers13194898

Ejemplares similares

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
por: Todoerti, Katia, et al.
Publicado: (2021)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
por: Todoerti, Katia, et al.
Publicado: (2021)

Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2022)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

P849: DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT.
por: Favasuli, V., et al.
Publicado: (2022)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2018)

LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?
por: Taiana, Elisa, et al.
Publicado: (2020)

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
por: Ronchetti, Domenica, et al.
Publicado: (2020)

P875: ACTIVATION OF LNCRNA NEAT1 LEADS TO SURVIVAL ADVANTAGE OF MULTIPLE MYELOMA CELLS BY SUPPORTING A REGULATORY LOOP WITH DNA REPAIR PROTEINS: RATIONAL BASES FOR NEAT1 THERAPEUTIC TARGETING IN THE DISEASE
por: Taiana, E., et al.
Publicado: (2022)

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature
por: Lionetti, Marta, et al.
Publicado: (2016)

In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
por: Lionetti, Marta, et al.
Publicado: (2015)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Long non-coding RNAs in B-cell malignancies: a comprehensive overview
por: Nobili, Lucia, et al.
Publicado: (2017)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine
por: Simeon, Vittorio, et al.
Publicado: (2015)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
por: D’Aquila, Patrizia, et al.
Publicado: (2021)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?
por: Molica, Stefano, et al.
Publicado: (2009)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
por: Cifola, Ingrid, et al.
Publicado: (2015)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Long Non-Coding RNAs in Multiple Myeloma
por: Nobili, Lucia, et al.
Publicado: (2018)

Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
por: Taiana, Elisa, et al.
Publicado: (2021)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
por: Agnelli, Luca, et al.
Publicado: (2019)

Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression
por: Biasiolo, Marta, et al.
Publicado: (2011)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_896l1oik6g9vqt8meru5ulv8uq